Cargando…
Economic Impact of Early-in-Hospital Diagnosis and Initiation of Eculizumab in Atypical Haemolytic Uraemic Syndrome
BACKGROUND: Atypical haemolytic uraemic syndrome (aHUS) is a rare, potentially life-threatening condition caused by dysregulation of the complement pathway. Eculizumab is currently the only approved treatment for this disorder. OBJECTIVE: Our objective was to investigate the impact of early administ...
Autores principales: | Ryan, Michael, Donato, Bonnie M. K., Irish, William, Gasteyger, Christoph, L’Italien, Gilbert, Laurence, Jeffrey |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7045788/ https://www.ncbi.nlm.nih.gov/pubmed/31828738 http://dx.doi.org/10.1007/s40273-019-00862-w |
Ejemplares similares
-
Current evidence on the discontinuation of eculizumab in patients with atypical haemolytic uraemic syndrome
por: Macia, Manuel, et al.
Publicado: (2017) -
Eculizumab in secondary atypical haemolytic uraemic syndrome
por: Cavero, Teresa, et al.
Publicado: (2017) -
Eculizumab in paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome: 10‐year pharmacovigilance analysis
por: Socié, Gérard, et al.
Publicado: (2019) -
Early treatment with eculizumab in atypical haemolytic uraemic syndrome
por: Garjau, Maria, et al.
Publicado: (2012) -
Outcome of atypical haemolytic uraemic syndrome relapse after
eculizumab withdrawal
por: Duineveld, Caroline, et al.
Publicado: (2020)